Loading data for IMMP — first visit, this takes a few seconds.
Immutep Limited (IMMP)
NasdaqGM: IMMP
· 实时价格 · USD
0.38
+0.01 (2.70%)
收盘价: Sep 02, 2026, 5:55 PM
股价、关键数字和最新消息,都在这一页。
Immutep Limited(IMMP)股价、分析与数据
暂无数据
| 买价 | 0.29 |
| 市值 | 55.4M |
| 营收(TTM) | 19.9M |
| 净利润(TTM) | -79.3M |
| 2.19 | |
| -0.39 | |
| n/a | |
| -1.45 | |
| 市净率(TTM) | 0.78 |
| 市销率(TTM) | 2.78 |
| 财报日期 | Feb 23, 2027 |
| 卖价 | 0.5 |
| 成交量 | 115,868 |
| 20日均量 | 290,241 |
| 开盘价 | 0.38 |
| 前收盘价 | 0.37 |
| 日内区间 | 0.37 - 0.39 |
| 52周区间 | 0.29 - 3.53 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 IMMP
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clin...
公司完整简介财报意外
Immutep 已于 Invalid Date 发布季度财报:
- 营收为 n/a 低于预期 $0, , NaN% 同比增长.
- 每股收益为 低于预期 , , NaN% 同比增长.